中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.019 seconds)

    Apo A-I mimetic peptides and methods of treatment
    6.
    发明授权
    Apo A-I mimetic peptides and methods of treatment 失效
    Apo A-I模拟肽和治疗方法

    公开(公告)号：US08748394B2

    公开(公告)日：2014-06-10

    申请号：US13774464

    申请日：2013-02-22

    Applicant: Abbott Cardiovascular Systems Inc.

    Inventor： Katsuyuki Murase ,  Li Zhao ,  Irina Astafieva ,  Paul M. Consigny

    IPC: A61K38/16 ,  A61K38/10 ,  C07K7/00 ,  C07K14/00

    CPC classification number: A61K38/17 ,  A61K31/661 ,  A61K38/10 ,  A61K38/1709

    Abstract: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I.

    Abstract translation: 一种方法，包括使输送装置通过血管的内腔前进到血管中的特定区域; 并将合成的载脂蛋白A-1（Apo A-I）模拟肽引入特定区域的血管壁，其中该肽具有使肽在反向胆固醇转运中有效的性质。 包含合适的载脂蛋白AI（Apo AI）模拟肽或Apo AI合成肽和Acyl CoA胆固醇：酰基转移酶（ACAT）抑制剂的组合的组合物，其形式适于递送到血管中，所述肽包含氨基酸 序列以与内源性Apo AI相关肽的顺序相反的顺序。 一种组合物，其包含适于递送至血管的形式的载脂蛋白A-1（Apo AI）合成肽，所述肽包含相对于内源性Apo AI具有较少氨基酸残基的氨基酸主链和螺旋1的嵌合体， Apo AI的螺旋9。

    Method of treating malignant solid tumors
    8.
    发明授权
    Method of treating malignant solid tumors 有权
    治疗恶性实体瘤的方法

    公开(公告)号：US09186329B2

    公开(公告)日：2015-11-17

    申请号：US13749612

    申请日：2013-01-24

    Applicant: Abbott Cardiovascular Systems Inc.

    Inventor： Paul M. Consigny

    IPC: A61K9/14 ,  A61K9/127 ,  A61K9/16 ,  A61K31/335

    CPC classification number: A61K9/146 ,  A61K9/127 ,  A61K9/1273 ,  A61K9/14 ,  A61K9/1629 ,  A61K31/335

    Abstract: This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of a drug capable of inhibiting mTOR and/or inhibiting an efflux pump and/or inhibiting HIF-1α and VEGF, the drug in particular being selected from the group consisting of sirolimus, everolimus, zotarolimus, tacrolimus, iolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, novolimus, 40-O-(3-hydroxypropyl), 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-tetrazolylrapamycin, the drug being administered along with a chemotherapeutic agent and/or radiation therapy.

    Abstract translation: 本发明涉及通过施用能够抑制mTOR和/或抑制外排泵和/或抑制HIF-1α和VEGF的药物来治疗实体瘤癌症，特别是难治性癌症的方法，该药物特别是选自组 由西罗莫司，依维莫司，佐他莫司，他克莫司，依维莫司A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司，诺罗维司40-O-（3-羟丙基），40-O- [2-（2-羟基）乙氧基] 雷帕霉素和40-O-四唑基雷帕霉素，该药物与化学治疗剂和/或放射治疗一起施用。

Patent Agency Ranking